Dechert Advises Robocath on its €40 Million Series C Financing Round

April 30, 2020 / PARIS – Dechert advised Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, in connection with its €40 million (US$43 million) series C round of financing. In connection with this financing, Dechert is advising Robocath in its strategic agreement signed with MicroPort, a leading global developer, manufacturer and operator focusing on minimally invasive intervention products for the treatment of vascular diseases and pathological changes, to set up a China-based joint-venture company, for the commercialization of its first robotic-assisted platform to the Asian market.

The transaction was led by MicroPort Scientific Corporation, a major listed industrial player in the cardiovascular field, with participation from institutional investors (Zhejiang Silk Road Fund, Luxembourg CLIIF managed under TUS-Holdings, CS Group and Anaxago), as well as existing Robocath investors (GO CAPITAL, NCI, Cardio Participations, M Capital, Supernova Invest, Normandie Participations, Crédit Agricole Normandie, Unexo, Caisse d’Epargne Normandie). 

The financial payment of €40 million will enable the company to aggressively expand its sales and marketing efforts for its first robotic-assisted platform, R-One™. It will also allow the company to broaden and accelerate the product development of its second-generation robot to address more PCI procedures and start peripheral and neurovascular applications. 

A multi-disciplinary team from Dechert’s Paris office, advised Robocath on the following:

• Corporate aspects:
  • On the investment: Anne-Charlotte Rivière, partner, with Louis Taslé d’Héliand, associate;
  • On the joint-venture  Ermine Bolot, partner, with Vianney Toulouse, associate;
• Regulatory aspects and foreign investment in France: Sophie Pelé, national partner; and
• Intellectual property aspects: Marie Fillon, national partner.